InsidersTradesSigma
Editas Medicine, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Editas Medicine, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Editas Medicine, Inc. has logged 148 reports. Market capitalisation: €415.9m. The latest transaction was filed on 5 March 2025 (Cession). Among the most active insiders: Eaton Bruce. Every trade is accessible without an account.
148
Insider Decl.
0
Thresholds
€235,203
30 ops.
Buy Volume
€3m
54 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Editas Medicine, Inc. Buy (bullish), based on 9 analysts. Average price target: US$5.78.
42Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 5 March 2025
Declarations148 total
2,891 shares@ US$1.71077.4% of flowCommon StockSEC:0001650664-25-000025:0
16,632 shares@ US$1.710717.6% of flowCommon StockSEC:0001650664-25-000026:0
4,109 shares@ US$1.71085.5% of flowCommon StockSEC:0001650664-25-000027:0
1,618 shares@ US$2.07742.1% of flowCommon StockSEC:0001650664-24-000126:0
541 shares@ US$2.07721.5% of flowCommon StockSEC:0001650664-24-000124:0
1,555 shares@ US$3.42473.1% of flowCommon StockSEC:0001650664-24-000103:0
518 shares@ US$3.42472.3% of flowCommon StockSEC:0001650664-24-000105:0
11,886 shares@ US$5.415692.6% of flowCommon StockSEC:0001650664-24-000090:0
6,619 shares@ US$5.205644.7% of flowCommon StockSEC:0001650664-24-000087:0
511 shares@ US$5.49563.6% of flowCommon StockSEC:0001650664-24-000075:0
12,191 shares@ US$5.495639.9% of flowCommon StockSEC:0001650664-24-000076:0
22,337 shares@ US$5.614294.5% of flowCommon StockSEC:0001650664-24-000044:0
45,000 shares@ US$5.6415100.0% of flowCommon StockSEC:0001650664-24-000039:0
Ideal exit: 7 Feb 2025 (T+270)
50,900 shares0Common StockSEC:0001650664-24-000013:0
24,800 shares0Common StockSEC:0001650664-24-000017:0
130,700 shares0Common StockSEC:0001650664-24-000015:0
35,300 shares0Common StockSEC:0001650664-24-000019:0
103 shares@ US$10.89720.8% of flowCommon StockSEC:0001650664-23-000029:0
695 shares@ US$8.20964.0% of flowCommon StockSEC:0001650664-23-000022:0
139 shares@ US$8.400.8% of flowCommon StockSEC:0001650664-23-000019:0
103 shares@ US$8.820.6% of flowCommon StockSEC:0001650664-23-000002:0
702 shares@ US$8.59354.1% of flowCommon StockSEC:0001415889-23-012264:0
141 shares@ US$8.390.8% of flowCommon StockSEC:0001415889-23-012049:0
45,167 shares0Common StockSEC:0001415889-23-011455:0
4,317 shares@ US$8.8047.9% of flowCommon StockSEC:0001415889-23-011382:0
25 of 148 declarations
About Editas Medicine, Inc.
Editas Medicine, Inc. is a U.S.-based biotechnology company listed on the NASDAQ in the United States. Headquartered in Cambridge, Massachusetts, with an operational site in Boulder, Colorado, the company is positioned in the highly innovative and highly volatile gene-editing segment. Founded in 2013 under the original name Gengine, Inc., it later adopted the Editas Medicine name that same year. The company’s identity is closely tied to CRISPR science, with a focus on translating CRISPR/Cas9 and CRISPR/Cas12a genome-editing systems into therapeutic programs. ([editasmedicine.com](https://www.editasmedicine.com/about/?utm_source=openai)) Editas is still best described as a clinical-stage, pre-commercial biotech rather than a revenue-generating pharmaceutical business. Its value proposition depends on scientific execution, regulatory milestones, and eventual commercialization, not on current product sales. The company’s pipeline is centered on transformative medicines for serious diseases with limited treatment options. Its lead in vivo candidate is EDIT-401, designed to treat hyperlipidemia, while EDIT-301 is an ex vivo gene-editing program being developed for hematologic diseases such as sickle cell disease. In earlier phases of the company’s development, Editas also advanced EDIT-101 in ophthalmology, underscoring the breadth of its platform approach. ([editasmedicine.com](https://www.editasmedicine.com/about/?utm_source=openai)) From a competitive standpoint, Editas operates in a field characterized by intense R&D competition, high technical barriers, and substantial clinical and regulatory risk. Its differentiation rests on deep CRISPR expertise and an increasing strategic emphasis on in vivo gene editing. Management has highlighted encouraging preclinical evidence for EDIT-401, including strong LDL-C reduction in non-human primates, which supports the program’s potential as a first-in-class or best-in-class contender in a large cardiometabolic market. ([ir.editasmedicine.com](https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-first-quarter-2026-results-and?utm_source=openai)) Recent developments have been important. In the first quarter of 2026, Editas said it remained on track to file an IND or CTA for EDIT-401 by mid-2026 and expects initial in-human proof-of-concept data by year-end 2026. The company also presented new preclinical EDIT-401 data at scientific meetings in spring 2026. In addition, Editas reported a favorable procedural development in its CRISPR patent dispute, with the U.S. Patent and Trademark Office reaffirming a prior Broad Institute victory in the interference proceeding involving CRISPR/Cas9 rights. For investors, Editas is therefore a speculative biotechnology name with meaningful upside optionality, but one that remains dependent on clinical progress, regulatory execution, and intellectual-property outcomes. ([ir.editasmedicine.com](https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-first-quarter-2026-results-and?utm_source=openai))
